
Breast Oncologist, Researcher, Brazil. @ESOncology Fellow Interest: #breastcancer #clinicalresearch Instagram @katsukitiscoski Follow @oncoalert
Porto Alegre, Brasil
Joined August 2016
- Tweets3K
- Following1.7K
- Followers1.3K
- Likes18.3K
Katsuki Arima retweeted
Our short comment about PROTEUS 1 is out in @NEJM
✨ @MarioTerlizziFR @GFRU_RO
nejm.org/doi/10.1056/NEJMc26…
Katsuki Arima retweeted
FDA approves #giredestrant + everolimus for ER+/HER2- MBC.
As I expected, the FDA approved it only for ESR1-mutant tumors (#evERA: PFS 10.0 vs 5.5 mo, HR 0.38).
For non-mutated tumors after CDK4/6i, options remain extremely limited, making the #gedatolisib approval (VIKTORIA-1) in that population critical.
Katsuki Arima retweeted
List of 12 Approvals given in breast cancer by @usfda from 1st May 2026 till 16 th November 2026. For quick summary. #BCSM #OncoWisdom @DrUddiGoswami @dr_yakupergun @OncBrothers
Katsuki Arima retweeted
FDA approved today Giredestrant plus everolimus for ESR1-mutated ER+/HER2- MBC. evERA: PFS 10.0 vs 5.5 months, HR 0.38.
ESR1m MBC now, simplified:
On 1L AI + CDK4/6, ESR1 emerges on ctDNA → camizestrant switch
Progression, after long CDK4/6 benefit → SERD alone
Progression, after shorter benefit or more disease → giredestrant + everolimus
PIK3CA/AKT1/PTEN altered, ESR1 wild type → capivasertib + fulvestrant
Visceral crisis → ADC or chemo
The catch: each drug is tied to a different ctDNA assay. FoundationOne Liquid CDx for giredestrant. Guardant360 CDx for elacestrant and camizestrant. The first test you order can decide what your patient gets.
Retest ctDNA at every progression. #bcsm
fda.gov/drugs/cancer-approva…
Katsuki Arima retweeted
Everolimus-associated stomatitis: a practical guide to prophylaxis.
Katsuki Arima retweeted
The evERA study / giredestrant approval is interesting because the @FDA did not approve the drug for the whole study population. The evERA trial accrued for tumors w/w/o ESR1 mutations. The overall result was positive. But study was designed to focus on ESR1 mutated tumors, and there was no/minimal benefit in ESR1 wildtype cohort. So FDA only granted approval into the already-crowded space of 2nd line ET for ESR1 mutated tumors. Here are data from @NEJM Supplemental appendix for the ESR1 wt subset (below).
📣 Today #FDA approved giredestrant in combination with everolimus for adults with ER+/HER-/ESR1 mutated #MetastaticBreastCancer after prior endocrine therapy in adjuvant or advanced setting.
More detailed info here: fda.gov/drugs/cancer-approva….
#OncTwitter #bcsm #MedTwitter
Katsuki Arima retweeted
2026 will be remembered as a truly transformative year in breast oncology
List of 12 Approvals given in breast cancer by @usfda from 1st May 2026 till 16 th November 2026. For quick summary. #BCSM #OncoWisdom @DrUddiGoswami @dr_yakupergun @OncBrothers
Exciting news! Today the FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. First approval for giredestrant!! FDA.gov. @OncoAlert @OncBrothers
Katsuki Arima retweeted
Evolving First-Line Treatment Strategies in ERBB2-Positive Metastatic Breast Cancer
jamanetwork.com/journals/jam…
Katsuki Arima retweeted
15-year results from NSABP B42. Extended AI after prior AI therapy led to a small yet significant advantage in 15y recurrence rate, mostly seen in node-positive disease (DRFS delta 4.4% N+, vs 1.6% N-). Important data to inform pts when deciding whether to extend ET. #ESMO26
Katsuki Arima retweeted
TALENT—neoadj TDXd (6-8 cycles) +/- AI in HER2 low HR+ early stage breast ca
ypCR // RCB
TDXd 7% // 16%
T-DXd/AI: 3% // 9%
T-DXd→ TC: 17% // 17%
Author concludes “modest” benefit; I would say “disappointing”. ypCR just isn’t the same endpoint w/ ER+ disease #ESMO26 @OncoAlert
Katsuki Arima retweeted
Today at #ESMO26, the 6-year results of NATALEE will be presented. Ahead of the presentation, my personal view on the survival gains with adjuvant CDK4/6 inhibitors…
The 6-year OS rates in NATALEE were 91.86% vs 89.73%: an absolute gain of 2.1 percentage points (HR 0.809; 95% CI 0.661–0.989; nominal one-sided p=0.019).
The absolute 7-year OS gain in monarchE was 1.8 percentage points (HR 0.842; p=0.027). I do not think these gains should be dismissed as “only 2%.”
In the EBCTCG analysis, adding taxanes to anthracycline-based chemotherapy—an approach we have accepted as standard for years—provided an absolute 5-year OS gain of approximately 1.9 percentage points. The populations and follow-up periods differ, so we cannot directly compare treatment efficacy. However, the standards we use to judge a few percentage points of survival benefit should be consistent.
Moreover, 95.4% of patients in monarchE had already received chemotherapy. This survival gain represents an additional benefit on top of chemotherapy and endocrine therapy.
Patient selection, toxicity, treatment duration, and cost certainly deserve discussion. However, the survival benefit of adjuvant CDK4/6 inhibitors in appropriately selected patients should not be underestimated.
#ESMO26 | NATALEE – 6-year results (Pre-presentation abstract)
6-year OS: 92.73% vs 89.38% (HR 0.809; nominal p=0.019).
iDFS: HR 0.741; absolute benefit of 4.1% at 6 years.
In monarchE, a 7-year OS benefit was demonstrated (HR 0.842; p=0.027).
NATALEE also shows a promising OS signal; however, formal statistical significance has not yet been established.
Looking forward to the presentation....
Katsuki Arima retweeted
PROs from lidERA presented by @GustavoWerutsky. Giredestrant appeared associated with comparable QoL vs standard ET. We don’t every day see a drug that improves adjuvant outcomes without adding side effect burden. #ESMO26 #ESMOAmbassadors
Katsuki Arima retweeted
Persistent benefit of extending AI therapy after 5 years to 10 years in NSABP B-42, with 3% absolute reduction in metastatic breast cancer at 15 yrs. Esp in higher risk node-positive cancers (4.4% vs 1.6%). But you have to wait 5+ years to see the difference. No diff in osteoporotic fractures or thrombotic events. Studies of newer interventions (e.g. SERDs, CDK46i) in the adjuvant setting that do not mandate 10 years of ET are not providing true standard of care.
Katsuki Arima retweeted
NATALEE study @myESMO shows persistent iDFS and emerging OS signal. Given treatment options for MBC, the treatment upon recurrence matters. Fewer than half the patients in the ET-alone arm get CDK46i on recurrence. Which poses the question: how relevant are OS data to US/OECD outcomes? In the online publication, the OS difference is smaller, and not statistically significant, in US/Western Europe.
annalsofoncology.org/article…
Katsuki Arima retweeted
📌Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis
🔗 thegreenjournal.com/article/…
@Icro_Meattini @LucaVisani2 @OncoAlert #OncoAlertAF #FlorenceConsensus26
👉🏻Safety of concurrent RT was evaluated across T-DM1, T-DXd, and SG.
👉🏻Twenty-nine studies including 3,817 patients were systematically reviewed.
👉🏻Severe extracranial RT toxicity remained uncommon across ADC classes.
👉🏻Intracranial RT identified T-DM1 as the only ADC with a consistent safety signal.
👉🏻No comparable radionecrosis signal was observed with T-DXd or SG.
Katsuki Arima retweeted
Nunca antes na história deste país se viu um presidente usar tanto a máquina estatal para comprar votos. Se Lula perder mesmo assim - e vai perder! - será a maior humilhação já vista a um político. O povo cansou do PT! Falta pouco para aposentar esse populista safado!!!
Katsuki Arima retweeted
This is an important article. A US-based, randomized study shows no benefit to focal ablation of asymptomatic metastatic disease in advanced breast cancer. Such approaches should not be considered standard of care.
Now out in #JCO!
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. Co-authored by @Docace911
Read the article. bit.ly/3VGspka
#BreastCancer #bcsm



































